Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Logistics who wrote (26490)	12/11/1998 1:19:00 PM
From: SpongeBrain	Read Replies (3) \| Respond to of 119973

I heard the same about ASTM! (DRAXF WILL GAP) eom

To: Logistics who wrote (26490)	12/11/1998 1:22:00 PM
From: Bill on the Hill	Respond to of 119973

DRAXF - $10,000,000 BEFORE THE END OF 98. The receipt of this FDA clearance for CDS entitles DRAXIS to receive a US$10 million milestone payment from Pfizer which DRAXIS expects will be paid prior to the end of 1998. In addition, DRAXIS will now receive royalties from the revenue generated from sales in the US attributed to CDS, as well as those from Cushing's disease.

To: Logistics who wrote (26490)	12/11/1998 1:24:00 PM
From: R Hamilton	Respond to of 119973

my dog made me do it......... bot draxf little downside...lots of promise! DRAXIS Health Reports Third Quarter Results; Acquisitions Fuel 6th Consecutive Quarter of Greater Than 50 Percent Year Over Year Revenue Growth MISSISSAUGA, ONTARIO--(BUSINESS WIRE)--Nov. 18, 1998--Draxis Health Inc. (NASDAQ:DRAXF) (TSE:DAX.) DRAXIS Health Inc. today reported results for the third quarter of 1998. Product revenues were $9,828,000, 59 percent higher than the previous year's third quarter which represents the sixth consecutive quarter in which year-over-year increases in product revenues were in excess of 50 percent. In commenting on the third quarter results, Dr. Martin Barkin, President and CEO of DRAXIS, stated: "DRAXIS has emerged as a diversified pharmaceutical company having achieved the objectives of revenue growth and full integration of R & D, manufacturing, marketing and sales in its various niche categories. Quarterly revenues have approximately tripled in less than 24 months as a result of acquisitions and intrinsic growth. Our pipeline is very advanced with five products submitted for regulatory approvals. Of these, the cognitive indication for Anipryl(R) in the United States is expected before year end. This approval is expected to fuel further growth in revenues and profitability in the coming quarters. Regulatory approval for Anipryl(R) is expected in the coming months from Australia. In Canada, we are awaiting approval of Alertec(R), the Company's product to treat narcolepsy." Dr. Barkin continued, "The research and development trials of Fibrimage(R), our innovative imaging product for deep vein thrombosis, has entered Phase II trials, and will be an important new platform of growth for the Company once approved. Amiscan(R), our myocardial infarct imaging agent, is also entering Phase II trials and we recently filed One Alpha D2 for osteoporosis. We are beginning to see the improvement in earnings performance that will be our focus in the quarters going forward. It is encouraging that absent the costs of launching SpectroDerm(R) in the United States, EBITDA would have been solidly positive in the third quarter."